Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus standard therapy in pediatric systemic lupus erythematosus
NL-OMON44106Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Belimumab plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Safety and tolerability. Planned start Aug 2012; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON44106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44106.